Franklin Resources Inc. Boosts Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Franklin Resources Inc. increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 1.2% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 501,807 shares of the medical research company's stock after purchasing an additional 6,011 shares during the period. Franklin Resources Inc. owned approximately 0.28% of IQVIA worth $117,031,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Blue Trust Inc. increased its stake in IQVIA by 702.9% during the second quarter. Blue Trust Inc. now owns 281 shares of the medical research company's stock worth $59,000 after purchasing an additional 246 shares during the period. Milestone Asset Management LLC grew its stake in shares of IQVIA by 15.0% in the second quarter. Milestone Asset Management LLC now owns 1,716 shares of the medical research company's stock worth $363,000 after acquiring an additional 224 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its stake in shares of IQVIA by 2.6% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 513,221 shares of the medical research company's stock valued at $108,515,000 after acquiring an additional 13,095 shares in the last quarter. Continuum Advisory LLC boosted its holdings in IQVIA by 3.3% in the second quarter. Continuum Advisory LLC now owns 1,538 shares of the medical research company's stock valued at $325,000 after purchasing an additional 49 shares during the period. Finally, First Citizens Bank & Trust Co. grew its stake in IQVIA by 12.1% during the 2nd quarter. First Citizens Bank & Trust Co. now owns 3,778 shares of the medical research company's stock worth $799,000 after purchasing an additional 409 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Stock Performance

Shares of NYSE:IQV traded down $1.97 on Monday, reaching $197.09. The company's stock had a trading volume of 1,804,661 shares, compared to its average volume of 1,188,671. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The stock's 50-day moving average is $212.24 and its two-hundred day moving average is $224.20. The stock has a market capitalization of $35.77 billion, a P/E ratio of 26.12, a PEG ratio of 2.05 and a beta of 1.49.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on IQV shares. Leerink Partners reiterated an "outperform" rating and issued a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Truist Financial decreased their price target on shares of IQVIA from $265.00 to $261.00 and set a "buy" rating for the company in a research note on Thursday. Morgan Stanley dropped their price objective on shares of IQVIA from $280.00 to $265.00 and set an "overweight" rating on the stock in a research report on Monday, November 4th. TD Cowen decreased their price objective on shares of IQVIA from $270.00 to $255.00 and set a "buy" rating for the company in a research report on Friday, November 1st. Finally, Bank of America dropped their target price on IQVIA from $255.00 to $235.00 and set a "buy" rating on the stock in a report on Friday. Four research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $256.19.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.